On Feb .6th, led by Director CHEN Ling of Guangzhou Institute of Biomedicine and Health (GIBH), a delegation of scientific researchers of the institute paid a visit to the National Center for Drug Screening in Shanghai Hi-Tech Industry Park. The delegation was warmly welcomed by Dr. WANG Weiming, Director of the Screening Center.
The National Center for Drug Screening was established in 1997, by the joint endeavor of the Ministry of Science and Technology, the Chinese Academy of Sciences, and Shanghai Municipal Government, and has passed through the estimation and acceptance inspection of the Ministry of Science and Technology. After years of efforts and accumulation, fruitful results have been achieved by the Screening Center, especially the recent breakthrough in the research field of Non-peptide small molecular glucagon-like peptide receptor-1 agonist, and the discovery of novel-type raloxifene deviation. Due to these achievements, the Center has attracted a lot of attention from the industry giants in the medical circle and made much cooperation realized.
Communications were held between the scientists of GIBH and Dr. Wang concerning mechanisms for innovative drugs R&D and effective management, further more, a preliminary intent for future collaboration has been reached by both sides. Director CHEN Ling of GIBH expressed his appreciation of the obtained accomplishments by the National Center for Drug Screening as well as the salutary values of its operational and managerial experiences for the intended plan for establishing a screening center in South China.
After the discussion, the delegation also visited the laboratories of the Screening Center.